Glutamatergic Neurosystem in FXS | MyFXResearch Portal

MGH/Harvard Study: Assessment of Glutamatergic Neurosystem in Fragile X Syndrome for Targeted Therapy

MGH/Harvard is recruiting adult males with Fragile X syndrome, 18 years or older, for a neuroimaging study. Participants will be compensated up to $350.

The aim of the study is to examine problems with a chemical messenger called glutamate in the brain in Fragile X syndrome, and how it impacts sensory, motor and cognitive abilities and implicated structural and functional connectivity.

Three visits at Massachusetts General Hospital are required:

Medical history and behavioral testing (approx. 1.5 hours)
PET-MRI (approx. 2 hours)
Magnetoencephalography (approx. 1 hour).

The study started on March 15, 2018, and ends by June 30, 2020. The IRB approval number is 2017P001039.

Travel/time subsidy: compensation up to $350 for participation.

If you are interested, please contact:

Maria Mody, PhD
maria@nmr.mgh.harvard.edu
(617) 726-6913

Our Most Recent Opportunities

If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.

Study: Autonomic and Sensory Functioning in Infants with FMR1 Conditions

Dr. Jane Roberts and the research staff at the Neurodevelopmental Disorders Laboratory at USC are conducting a research study to learn about the development of infants with Fragile X syndrome and Fragile X premutation over the first few years of life.

Survey: Research experiences in Fragile X Families

The Brain and Biomarker Lab at the University of Oklahoma is conducting a survey to learn about experiences with research, particularly biomedical research, in families with Fragile X syndrome (FXS).

Study: Language Study for Children and Adolescents with Fragile X syndrome

Researchers at the University of Wisconsin-Madison and the University of Massachusetts-Amherst are conducting a study to learn about links between learning and language in Fragile X syndrome.

Survey: Fragile X Nutrition Survey

The University of Wisconsin-Madison is conducting a survey to learn about associations between infant feeding and neurodevelopment in children with Fragile X syndrome.

Clinical Trial: Phase 2B/3 Studies of BPN14770 in Fragile X syndrome

Tetra Therapeutics is conducting a two randomized, placebo-controlled studies of BPN14770/zatolmilast to learn about the experimental drug’s safety and efficacy for males ages 12-45.

Survey: Developing a Gold Standard for Tracking Adult Functional Outcomes in Developmental Disabilities (AFS Study)

University of Pittsburgh is conducting this research to develop the Adult Functioning Scale (AFS), a new survey being designed to capture outcomes in the areas of social functioning, employment, independence, and satisfaction for individuals with various developmental disorders.